Parham Habibzadeh: ctDNA MRD After CRLM Resection Identifies Who Benefits From ACT!
oncodaily - Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT! Upfront surgery: MRD+ patients improved with […]
AI Summary: A growing body of evidence shows circulating tumor DNA (ctDNA) measured after colorectal liver metastasis resection can identify which patients truly benefit from adjuvant chemotherapy and who likely do not. This blood test promises more personalized postoperative care, reducing unnecessary toxicity and costs by targeting chemo to molecular minimal residual disease rather than gut instinct.
Related Stories
Prosigna-guided OPTIMA trial shows chemo can be safely skipped in many ER+/HER2− breast cancers / 5 wks
National study to use genetic testing to guide cancer survivor follow-up / 1 month
Ultrasensitive HPV blood test detects head and neck recurrence months earlier / 25 days
Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 5 wks
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 5 wks
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 5 wks
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supply Chain, Nutrition, Autism, Pfizer and look for the RSS link.
StackHealth Time Machine